Premium
3D molecular imaging of the “angiogenic switch” differentiates neovascular development in animal models of cancer
Author(s) -
Caruthers Shelton D,
Schmieder Anne H,
Williams Todd A,
Allen John S,
Zhang Huiying,
Winter Patrick M,
Wickline Samuel A,
Lanza Gregory M
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.470.12
Subject(s) - angiogenesis , medicine , neovascularization , animal model , adenocarcinoma , cancer , pathology , cancer research
The objective of this study was to determine whether neovascular progression in animal tumor models could be resolved and differentiated noninvasively with high‐resolution MR molecular imaging and 3D neovascular mapping techniques. Methods Rabbits implanted with Vx2 adenocarcinoma and nude mice implanted with MDA435 cells were imaged with MR at clinically relevant field strengths (3T) before and after administration with α ν β 3 −targeted paramagnetic nanoparticles. Tumor volumes and 3D MR neovascular maps were obtained in rabbits on days 8, 14 and 16 and in mice on days 14 and 21 post implantation. Results On day 8, angiogenesis comprised 0.9± 0.3% of the Vx2 tumor peripheral volume, which increased to 3.8±0.7% and 7.9±1.7% on days 14 and 16, respectively (p<0.05) (Fig). In mouse xenograft tumors, angiogenesis was minimal at 14 days (0.4±0.2%) and increased (p>0.05) to 1.0 ±0.5% at 21 days. In both models, nontargeted tumors had minimal enhancement. Conclusion These data suggest that tumor growth of the MDA‐435 tumor may be diminished due to a muted inflammatory response in comparison with the robust “angiogenic switch” observed in the Vx2 model. MR molecular imaging and 3D neovascular mapping could have an important contribution in personalized medical treatment regimens incorporating an antiangiogenic arm. Support: NIH/NCI U54 CA 119342